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OBJECTIVES: Prior to being considered for funding at a provincial level, all oncolog-
ics must first be appraised at a national level by the pan-Canadian Oncology Drug 
Review (pCODR), except in Quebec. This research aims to explore whether there 
are any differences between the speed of provincial oncologic access and whether 
this varies by provincial wealth and/or population. METHODS: All publically avail-
able provincial funding summaries were extracted from the pCODR website up 
to October 2014 from which the appraisal outcomes and dates were extracted. 
The population, GDP and GDP per capita of each province was extracted from the 
Government of Canada statistics website. Statistical comparisons were performed 
using one-way ANOVA and Student’s t-tests. RESULTS: The average delay between 
pCODR recommendations and provincial funding decisions was 8.9 months, which 
significantly varied by province (p< 0.0001), with the lowest being British Columbia 
(2.8 months) and the highest being Prince Edward Island (15.1 months). The 4 prov-
inces with populations lower than 1 million experience significantly greater delays 
to access versus the 5 provinces whose population exceeded 1 million (12.4 vs. 6.1 
months, p< 0.005). The 4 provinces whose GDP exceeds CAD75,000 million experi-
ence significantly faster time to access than the 5 provinces whose GDP is lower than 
this (5.1 vs. 12.0 months, p< 0.005). However, this relationship does not reach sig-
nificance when GDP is examined on a per capita basis (top 4 provinces: 7.2 months 
vs. 10.3 months for the bottom 5, p= 0.11). CONCLUSIONS: There are significant 
variations in time to access for oncology drugs between different provinces. This is 
significantly related to the province population and overall wealth but not wealth 
on a per person basis. Further research can define whether this reflects differences 
in provincial assessments or whether pharmaceutical companies are prioritising 
larger provinces where better market returns can potentially be realised.
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OBJECTIVES: The pan-Canadian Oncology Drug Review (pCODR) makes recommen-
dations at a national level for oncology drugs. Drugs can only move to provincial 
consideration if they receive a pCODR “recommendation” or “recommendation 
conditional on cost-effectiveness being improved to an acceptable level”. This 
research aims to explore if pCODR deeming an oncologic to have acceptable cost-
effectiveness can affect the speed of attaining provincial access. METHODS: All 
publically available pCODR appraisal reports and provincial funding summaries up 
to 31 September 2014 were identified from which the appraisal outcomes, incre-
mental cost-effectiveness ratios (ICERs) and dates were extracted. If more than 1 
ICER was stated, the mean value was used. Statistical comparisons were performed 
using Student’s t-tests. RESULTS: pCODR submissions encompassing 34 indica-
tions were extracted. ICERs were only stated in 13/34 of these submissions. 2/13 
were pCODR-recommended, 11/13 recommended conditional on cost-effectiveness 
being improved to an acceptable level, and 0/13 rejected. There was no significant 
difference between average delay in provincial access for the submissions that 
received a full recommendation versus those that received a conditional recom-
mendation (9.3 vs 9.3 months, p= 0.49). However, the 7 drugs with an ICER above 
CAD200,000 per Quality–Adjusted Life Year (QALY) experienced significantly longer 
delays to provincial access than the 6 drugs whose ICERs fell below this level (12.3 
vs. 8.4 months, p= 0.02). CONCLUSIONS: Oncology drugs that are deemed to have 
acceptable cost-effectiveness by pCODR did not seem to attain faster provincial 
access, although this analysis was limited by the small number of positive pCODR-
recommendations with publically available ICERs. Nevertheless, oncologics with 
higher ICERs experienced significantly greater delays to provincial access. This sug-
gests that by making greater efforts to demonstrate cost-effectiveness at the level 
of pCODR, faster provincial and patent access can be obtained.
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OBJECTIVES: The Food and Drug Administration (FDA) have approved 28 onco-
logics across 37 indications on the basis of a clinical trial package lacking com-
parative Phase III data (Macaulay, ISPOR Toronto 2014). Approval was typically 
granted for indications with no therapeutic alternative where a response rate 
≥ 10% was demonstrated. This research aims to define the circumstances under 
which oncologics can obtain both regulatory approval and public reimbursement 
in Canada on this basis. METHODS: All pan-Canadian Oncology Drug (pCODR) 
final recommendations and Provincial Funding Summaries were analysed up to 
26th November 2014 and the supportive trial package and key rationale were 
extracted. RESULTS: 36 submissions were extracted. 4 were pCODR-appraised on 
the basis of single-arm Phase II trial data. 3/4 were recommended (brentuximab 
vedotin [Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma]) and 
vismodegib) with pCODR deeming randomized controlled trials (RCTs) to be not 
feasible due to very small patient numbers and there being no standard of care. All 
3 were also subject to additional restrictions to the approved label. Nevertheless, 
the incremental cost-effectiveness ratios (ICERs) generated on such data packages 
were regarded as highly uncertain; these recommendations were all conditional 
on cost-effectiveness being improved to an acceptable level. Nevertheless, within 
12 months of all these recommendations, provincial approval was attained in ≥ 5 
provinces including the largest 3 (Ontario, Alberta, and British Columbia). For the 
rejected submission (crizotinib), an RCT was deemed feasible and pCODR would 
not make a recommendation in the absence of comparative survival and quality 
of life benefits. A subsequent resubmission including Phase III data was recom-
mended. CONCLUSIONS: pCODR will recommend oncologics based on single-arm 
Phase II data for indications where RCTs are not deemed feasible but discounting 
promote market access leverage. METHODS: Across the United States, 100 medical 
and hematological oncologists and 25 managed care organization (MCO) pharmacy 
and medical directors completed online quantitative surveys to capture their views 
on BTD. RESULTS: Surveyed payers were unanimous that BTD will influence formu-
lary decisions for oncology drugs; some 40% said BTD would result in more favorable 
tier placement, while 37% expect fewer prescribing controls. However, none of our 
surveyed payers considered themselves yet very familiar with the BTD pathway. In 
contrast, one third of surveyed oncologists declared themselves to be very familiar 
with BTD. Furthermore, almost all oncologists said that BTD will affect their prescrib-
ing; almost 50% agreed that an agent with accelerated approval based on Phase II 
data and BTD will more likely be prescribed than such an agent without BTD. Notably, 
while BTD includes no guarantee of access to other regulatory pathways other than 
fast track designation, surveyed oncologists and payers often associate accelerated 
approval and priority review with BTD. CONCLUSIONS: BTD instills confidence in 
payers and prescribers, such that this accolade looks set to positively influence reim-
bursement conditions, drive uptake, and promote market access for a given agent. 
Moreover, associating BTD with accelerated approval and priority review likely further 
inspires positivity towards BTD agents. However, that payer respondents are at least 
somewhat unfamiliar with the BTD pathway must be considered. Manufacturers 
with BTD agents must formulate their market access strategy early and efficiently, 
ensuring that payers are fully aware of the benefits and advantages that secured 
this classification.
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OBJECTIVES: To capture the trends in opioid prescribing and to determine whether 
rural residency impacts opioid prescribing patterns. METHODS: We used the National 
Ambulatory Medical Care Survey (NAMCS) data available for the years 2006-2010. The 
NAMCS data is a nationally representative annual survey of the provision and utiliza-
tion of outpatient medical care services in the US. Main outcome measure was opioid 
drug prescribed. Survey weighted logistic regression models were fit to determine 
factors influencing opioid prescribing. RESULTS: Opioid prescriptions increased from 
10% in 2006 to 12% in 2010. There was an increasing trend in rural opioid prescribing 
(11% in 2006, 12% in 2007, 14% in 2008, 15% in 2009 and 2010) as compared with urban 
location (10% from 2006-2008, 12% in 2009 and 11% in 2010). Primary care physicians 
and medical professionals were more likely to prescribe opioids (13% in 2006, 12% in 
2007, 16% in 2008, 17% in 2009 and 14% in 2010) as compared with surgeons (6%, 11%, 
10%, 10%, 14% respectively). Multivariate analyses revealed that over the years, younger 
patients (35-49 and 50-64), who did not have a cancer diagnosis, and were insured by 
Medicare or other type of insurance were more likely to get opioid prescription, while 
patients seen by surgeons were less likely to get opioids. CONCLUSIONS: Our study 
poses significant implications for healthcare professionals and policy makers. Our 
study not only demonstrated that rural residents were more likely to be prescribed opi-
oids but it showed an upward trend in rural opioid prescribing which was significantly 
different from urban locations. Increased prescribing of opioids, has led to a growing 
problem of prescription drug abuse especially among rural residents. Further research 
is warranted to study the extent of over prescribing and abuse in rural communities.
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OBJECTIVES: The pan-Canadian Oncology Drug Review (pCODR) was established in 
2010 to appraise oncology drugs in order to help guide provincial reimbursement 
decision-making. pCODR is currently being transferred to Canadian Agency for Drugs 
and Technologies in Health (CADTH) offering the opportunity for reform. This research 
aims to measure the impact of this process on access to oncology drugs in Canada 
and compare this with Quebec, which does not refer to pCODR. METHODS: All pub-
lished pCODR and Institut national d’excellence en santÃ© et en services sociaux 
(INESSS, the Quebec Health Technology Assessment body) reports were identified 
alongside pCODR provincial funding summaries up to 30 September 2014 and the 
dates, decision, and key rationale were extracted. All statistical comparisons were 
made using ANOVA and t-tests. RESULTS: Most (62% [21/34]) pCODR recommen-
dations were conditional on cost-effectiveness being demonstrated (20% recom-
mended, 18% not recommended). Following pCODR recommendations, an average 
of 6.7 months from submission, there is an additional average 8.9 month delay for 
provincial funding decision-making. The time required for provincial decision making 
was no faster for drugs recommended by pCODR versus those conditional on accept-
able cost-effectiveness (9.3 vs. 9.3 months, p= 0.49). INESSS issued recommendations 
for these corresponding oncology drugs an average of only 2.1 months after pCODR, 
6.8 months before the other provinces, a difference which is statistically significant 
(p= 0.0013). CONCLUSIONS: Given that the key issue for most candidate oncologics 
facing reimbursement is cost-effectiveness, pCODR issuing large numbers of rec-
ommendations conditional on cost-effectiveness being demonstrated adds a time-
consuming step that does not speed provincial decision making. INESSS, operating 
independently to pCODR, issue recommendations significantly sooner than other 
provinces. Based on this, we recommend that acceptable pCODR cost-effectiveness 
be a mandatory requirement prior to provincial consideration or that the pCODR 
process be curtailed into just providing a clinical benefit assessment.
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sulfate (100%), Magnesium sulfate (100%) and Ondansetron (70%). In our study total 
cost of drugs (300974.4 rupees), in total cost Ondansetron has 14.7% and least was 
amlodipine of 0.018%. CONCLUSIONS: There are 32 adjunctive drugs used in inpa-
tient oncology department. The drug utilization study we conducted helped to know 
the prescribing and usage pattern of drugs in inpatient radiotherapy department, 
there by the indenting of drugs is very easy without any drug lackage. The cost 
considerations are helped for proper budget preparation.
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OBJECTIVES: Treatment for resected melanoma at high risk for progression has 
generally consisted of adjuvant interferon alfa-2b, the only adjuvant melanoma 
therapy approved in the US. This study sought to describe patterns of systemic adju-
vant therapy, clinical outcomes, and healthcare costs among melanoma patients 
treated in the US community oncology setting. METHODS: This was a retrospective 
observational study of adult patients with Stage I-III melanoma identified between 
1/1/2007 and 4/1/2013 in the Vector Oncology Data Warehouse. Descriptive statistics 
were used to describe patient demographic and clinical characteristics for those 
treated and untreated with systemic adjuvant therapy. Only patients who received 
interferon/peginterferon as their adjuvant systemic therapy were evaluated for 
treatment patterns and clinical outcomes including time to treatment initiation 
and disease-free survival (DFS). Total direct healthcare cost and costs associated 
with systemic therapy were calculated per patient per month (PPPM) based on 
imputation from billing record charges and utilization history. RESULTS: Of the 
636 patients identified, 149 (23.4%) were treated with adjuvant systemic therapy. 
Of these, 137 received interferon/peginterferon therapy. Median time from surgical 
resection to start of interferon/peginterferon was 2.6 months and median duration 
of therapy for patients treated with interferon was 3.5 months. Approximately, 75% 
of patients remained on therapy at one month and by one year, only 25% of the 
patients remained. Median DFS was a little more than three years (38.2 months). 
Median (IQR) total cost associated with first-line systemic therapy was $18,154 
($10,139, $38,477) PPPM; $13,416 ($8,190, $28,725) of that cost was attributable to 
interferon/peginterferon therapy (2014 dollars). CONCLUSIONS: This study suggests 
that in this community oncology setting, adjuvant melanoma treatment comprised 
mostly interferon/peginterferon therapy. Only 25% of patients received the full rec-
ommended 1-year course of interferon therapy. These results highlight the need for 
better and more tolerable treatments in the adjuvant setting.
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OBJECTIVES: Across geographies, governments and institutions are implementing 
additional administrative burdens on clinicians while prescribing high cost oncology 
products. In an effort to reduce prescriptions and control healthcare expenditure, 
these restrictions have been put in place as a means of prescription justification and 
to ensure careful thought has been invested into each patient. This research sought 
to investigate the prevalence, impact and outcomes of such schemes. METHODS: 
The research was conducted through in-depth interviews with payers and clinicians 
across 10 EMEA markets. RESULTS: In many markets studied, there are systems 
currently in place to ensure appropriate prescription of high cost products. These 
additional requirements may be manifested in supplemental forms that must be 
filled out by the prescribing clinician (e.g. Norway), online patient registrations 
and database entry (e.g. Italy), additional pharmacist justification (Saudi Arabia) 
or additional physician justification (e.g. Slovakia). CONCLUSIONS: Payers viewed 
some protocols as being more effective than others to combat adverse prescrip-
tion, while clinicians viewed them as being time consuming and often annoying. 
Interestingly, physicians found loop-holes as a way to avoid the additional burden 
and time required to prescribe high cost oncology products. Physicians were not 
concerned with these systems permanently restricting access of high cost products 
to their patients. However, their main concern was that these additional procedures 
are causing delays in the initiation of treatment and require additional effort.
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OBJECTIVES: The Cancer Care Quality Program (CCQP), a novel program by Anthem 
Inc. health plans designed to align reimbursement with evidence-based, cost-effec-
tive oncology treatment, collects clinical data that can be integrated with the admin-
istrative claims data in the HealthCore Integrated Research Database (HIRD). This 
study evaluated baseline characteristics of patients within oncology practices par-
ticipating in the CCQP. METHODS: Breast, colon, and lung cancer patients from prac-
tice sites participating in the CCQP were identified between 6/23/2014 and 12/3/2014 
(Intake Period). Patients were characterized based on the earliest request to utilize 
chemotherapy and/or supportive care medications (Index Date) during the Intake 
Period; analyses included patients with ≥ 6 months of continuous pre-index eligibil-
ity. CCQP clinical data was integrated with HIRD administrative claims data. Baseline 
characteristics were stratified by cancer type/stage and included: pathology, bio-
markers, ECOG performance status, and Deyo-Charlson Index (DCI). RESULTS: A 
total of 1,230 breast, 329 colon, and 554 lung cancer patients were identified with 
mean(SD) ages and DCI’s of 55(11), 58(10), and 62(9) and 5.7(3.2), 7.6(2.6), and 7.7(2.8), 
at a provincial level may be required to offset the inherent uncertainty in the 
resulting ICER estimation.
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OBJECTIVES: The Appalachia region experiences excess cancer mortality and a lack 
of access to cancer care resources. There is limited research examining adjuvant 
treatment use disparities in this region. This study aims to explore adjuvant endo-
crine therapy (AET) utilization in Appalachia, and delineate the effects of access 
to cancer on AET use. METHODS: We linked female breast cancer patients identi-
fied in cancer registries from the Appalachian counties in four states (KY, NC, OH, 
PA) to 2006-2008 Medicare claims data. We included patients with invasive, non-
metastatic, hormone-receptor-positive breast cancer and assessed the prevalence 
of receiving guideline-recommended AET. We then assessed AET adherence among 
those who received guideline-recommended AET using the Medication Possession 
Ratio (MPR), and determined non-persistence, defined as exceeding a 60-day medi-
cation gap. We also used survival analyses to examine the influences of adherence 
and persistence on overall survival. RESULTS: Only 450 of the 946 eligible patients 
(47.6%) received guideline-recommended AET, which was significantly associated 
with shorter travel time to receive care, dual Medicare and Medicaid eligibility, being 
unmarried (vs. married), and living in Pennsylvania (vs. Ohio). The non-adherence 
rate was about 31% and non-persistence rate was 30% over an average follow-up 
period of 421 days. Tamoxifen, relative to aromatases, was associated with higher 
odds of adherence (OR = 2.82, p < 0.001) and a lower risk of non-persistence (HR = 
0.40, p < 0.001). Side effects like pain may be an important factor leading to non-
adherence and early discontinuation. Non-adherence to and non-persistence with 
AET were associated with higher risks of all-cause mortality. CONCLUSIONS: In 
Appalachia, geographic and socioeconomic factors such as travel time to receive 
care and healthcare plan type are important elements that could contribute to 
disparities in access to adjuvant treatment, while treatment choice and medication-
related factors may exert strong influences on AET use behaviors.
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OBJECTIVES: Cancer survivors have been reported delaying or avoiding care due 
to costs. Cost-related medication nonadherence (CRN) is associated with worse 
health outcomes, including stroke, heart disease, and hospitalizations. This study 
was conducted to estimate the prevalence and factors of CRN among cancer sur-
vivors. METHODS: Using the 2013 Behavioral Risk Factor Surveillance System 
(BRFSS), we will examine self-reported CRN among cancer survivors. In total, 
491,773 subjects, including 44,968 (0.09%) cancer survivors, who reported CRN 
in the past 12 months were identified. Descriptive statistics and multiple logis-
tic regression models were used to characterize and to identify factors affecting 
CRN among cancer survivors. RESULTS: In a nationally representative sample 
of 44,968 cancer survivors, 3,328 (7.4%) were CRN-reported (851 men and 2,477 
women). Cancer survivors who reported CRN (n= 3,328) were younger, live in the 
South, more likely to be less educated, more likely to be female and Hispanic, 
and more likely to have health care coverage, lower household income, multiple 
comorbidities, poorer self-rated health status, and activity limitation. In adjusted 
analyses, men with younger age, black or Hispanic race, lower household income, 
no health care coverage, health care coverage, multiple comorbidities, poorer self-
rated health, and activity limitation were significantly more likely to report CRN. 
Women with younger age, Hispanic or other race, South living, lower household 
income, higher education, no health care coverage, health care coverage, multiple 
comorbidities, poorer self-rated health, and activity limitation were significantly 
more likely to report CRN. CONCLUSIONS: Significant gender-specific differences 
were found among factors related to CRN among cancer survivors. Given the high 
cost sharing under drug coverage, it is important to closely monitor CRN in high-
risk subgroups. Further studies are warranted to establish effective interventions 
in this vulnerable population.
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OBJECTIVES: The objective of adjunctive drug utilization pattern is to know the 
proportion of adjunctive drugs used in cancer inpatient’s , to improve the quality of 
health care, for proper planning of indenting and budgeting of adjunctive drugs in 
Oncology (Radiotherapy) Department. METHODS: The study was conducted in the 
Oncology (Radiotherapy) Department of Guntur Medical College and Government 
General Hospital, Guntur. The study method includes prioritizing the patients based 
on inclusion and exclusion criteria. Information regarding drug utilization is col-
lected with the aid of a data collection form from the inpatient’s case sheets. The col-
lected data will be tabulated and analyzed using suitable statistical tools. RESULTS: 
The most commonly observed cancer type was cervix ( 26.54%) followed by Head 
and Neck ( 23.9%). In our study, we observed that there is more prevlence(80%) of 
gynaecological cancers in women. There was female predominance (67%) in cancer 
prevalence. The present study shows maximum number of patients are between 
the age group of 40- 60 years (33.6%). The total drugs used in inpatient oncology 
department are 70450, among all the drugs 16015 are parenteral formulations, 
whereas 54435 are oral formulations. Ondansetron is the mostly used drug (17.5%) 
followed by diclofenac (12.7%) and ranitidine (12.5%). The drugs use for prevention 
of chemotherapy induced adverse drug reactions include mesna (100%), Potassium 
